Top Markets
#1 Black Phoenix Black Phoenix +21,376.82%
#2 Nesa Nesa +739.75%
#3 ADO Protocol ADO Protocol +101.64%
#4 Cortex Cortex +93.46%
#5 Ontology Gas Ontology Gas +76.57%
#6 Kinesis Silver Kinesis Silver +52.82%
#7 OpenEden OpenEden +38.13%
#8 Magma Finance Magma Finance +32.63%
#9 Biconomy Biconomy +23.61%
#10 QuantixAI QuantixAI +23.21%
Coin of the day
Black Phoenix Black Phoenix
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Viking Therapeutics, Inc. Viking Therapeutics, Inc.

Viking Therapeutics, Inc.

VKTX
Classifica tra le azioni #4205
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
Prezzo delle azioni
$34.55
Capitalizzazione di mercato
$4.03B
Variazione (1 giorno)
1.12%
Variazione (1 anno)
32.69%
Paese
US
Scambia Viking Therapeutics, Inc. (VKTX)

Categoria

Healthcare
Utile per Viking Therapeutics, Inc. (VKTX)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Viking Therapeutics, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Viking Therapeutics, Inc. dal 2026 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
Non abbastanza dati per le date fornite.
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH